STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology
chemistry

HCW Biologics Gains FDA Clearance for First-in-Human Trial of Novel Alopecia Areata Treatment

byLuca Blaumann
February 3, 2025
in Biotechnology, Small-Cap
Reading Time: 2 mins read
Share on TwitterShare on LinkedIn

Phase 1 Trial of HCW9302 Marks a Milestone in Autoimmune Disease Research

HCW Biologics (HCWB), a clinical-stage biopharmaceutical company specializing in innovative immunotherapies, has announced FDA clearance for its Investigational New Drug Application (IND) to begin a first-in-human Phase 1 clinical trial of HCW9302. This trial will evaluate the drug’s safety and efficacy in patients suffering from moderate-to-severe alopecia areata, an autoimmune disease characterized by sudden hair loss and a significant impact on psychological well-being.

HCW9302 is a groundbreaking interleukin 2 (IL-2) fusion protein complex developed using HCW’s proprietary TOBI platform technology. It functions by binding to IL-2αβγ receptors, primarily found on regulatory T (Treg) cells, which helps activate and expand these cells to suppress harmful immune and inflammatory responses. This mechanism offers hope for patients who currently have no FDA-approved curative treatments for alopecia areata.

Preclinical models have demonstrated HCW9302’s efficacy in treating autoimmune diseases at well-tolerated doses, showing potential beyond alopecia areata. The injectable, subcutaneous approach aims to reduce inflammation while minimizing the risk of broad immunosuppression.

Dr. Hing C. Wong, Founder and CEO of HCW Biologics, expressed enthusiasm about the FDA’s decision, stating, “This clearance brings us one step closer to offering a transformative immunotherapeutic for autoimmune diseases. While alopecia areata is not life-threatening, its psychological toll is profound, and current treatments often carry severe side effects.”

The primary goal of the Phase 1 trial is to establish a safe and effective dose of HCW9302 that boosts Treg cell activity. Success in this phase could lead to expanded trials targeting other autoimmune and inflammatory conditions, including graft rejection, atherosclerosis, diabetes, and neurodegenerative diseases.

Read original press release here

You might like this article:Trump’s New Tariffs Spark Global Retaliation and Trade War Fears

Tags: BreakingGrowthMoversNewsStock Market
Previous Post

Trump’s New Tariffs Spark Global Retaliation and Trade War Fears

Next Post

Palantir Reports Record Q4 Results, Solidifies Role in AI Revolution

Related Posts

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

byLuca Blaumann
August 5, 2025
0

Telehealth company maintains 2025 outlook, expands beyond GLP-1 offerings amid regulatory and partnership setbacks Hims & Hers Health (HIMS) stock...

ProMIS Neurosciences Soars 160% After FDA Fast Track Designation for Alzheimer’s Drug

byLiliana Vida
July 21, 2025
0

PMN310 aims to deliver a safer, next-generation treatment by targeting toxic amyloid-beta in early-stage Alzheimer’s patients Shares of ProMIS Neurosciences...

Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025

byLuca Blaumann
July 7, 2025
0

Following a 38-to-1 stock split and explosive rally, the biotech firm's volatile trading persists despite a multi-year loss streak Regencell...

Next Post

Palantir Reports Record Q4 Results, Solidifies Role in AI Revolution

Latest News

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million

Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

Based on Your Interest

Aerospace & Defense

Palo Alto Networks Eyes $20B Deal for CyberArk

July 29, 2025
trading-chart
Ecommerece

AMD and Amazon: Two Titans Poised for Explosive Growth

July 28, 2025
Entertainment

FCC Approves $8B Paramount-Skydance Merger Amid Political Controversy

July 25, 2025

Recommended

Aerospace & Defense

FAA Keeps Boeing 737 MAX Production Cap in Place Amid Ongoing Oversight

July 24, 2025
Large-Cap

Intel Beats on Revenue, Misses on Earnings; Cuts Workforce by 15%

July 24, 2025
Brokerages

Accelerant Soars in NYSE Debut, Valued at $6.4 Billion

July 24, 2025
Distributor

GoPro and Krispy Kreme Surge as Meme Stock Frenzy Reignites

July 23, 2025
Electrical Equipment

GE Vernova Soars to Record High on Raised Cash Flow Outlook

July 23, 2025
Stoxpo

Follow us on social media:

Highlights

  • Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast
  • Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom
  • Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk
  • Blade Air Mobility Sells Rideshare Business to Joby Aviation for $125 Million
  • Qualcomm Posts Strong Q3 Results, Fueled by Automotive and IoT Growth

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

Hims & Hers Shares Dip Despite Strong Growth as Revenue Misses Forecast

August 5, 2025
trading-chart-2

Palantir Surges Past $1 Billion Quarterly Revenue, Lifts Guidance Amid AI Boom

August 4, 2025
tesla

Tesla Board Approves $29 Billion Alternative Compensation Plan for Elon Musk

August 4, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?